Clinical Trials · NCT00635765

Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

Name: Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Octreotide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Ambrilia Biopharma, Inc.
Enrollment: 63
Start date: Oct 2007
Locations: 6 sites, 6 countries
Primary endpoint: Assess, for up to an additional 96 weeks, the safety profile of C2L-OCT-01 PR administered intra muscularly every 6, 5 or 4 weeks in patients who have completed the C2L-OCT-01 PR-301 study.

View Octreotide compound reference